| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 1 | T | 1 CC-486 + R-miniCHOP | 422 | 69 | 18 | 7 | 4 | 0 | 0 | 05/25/2021 | 178 | 65 |
| 2 R-miniCHOP | 67 | 17 | 8 | 4 | 0 | 0 | ||||||||
| 136 | 35 | 15 | 8 | 0 | 0 | |||||||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 1 | Y | 0 CD19 CAR T-cell Therapy | 396 | 135 | 88 | 49 | 24 | 11 | 0 | 06/12/2023 | 99 | 42 | |
| 135 | 88 | 49 | 24 | 11 | 0 | |||||||||
| 2 | Y | 1 Mosunetuzumab | 8 | 6 | 4 | 3 | 3 | 0 | 06/12/2023 | |||||
| 2 Polatuzumab | 8 | 6 | 4 | 2 | 1 | 1 | ||||||||
| 3 Mosunetuzumab + Polatuzumab | 7 | 4 | 3 | 1 | 1 | 0 | ||||||||
| 4 Observation | 6 | 4 | 2 | 0 | 0 | 0 | ||||||||
| 29 | 20 | 13 | 6 | 5 | 1 | |||||||||
| 3 | Y | 5 Mosunetuzumab + Polatuzumab | 3 | 3 | 2 | 2 | 0 | 0 | 06/12/2023 | |||||
| 3 | 3 | 2 | 2 | 0 | 0 | |||||||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 227 | 7 | 4 | 0 | 0 | 0 | 0 | 09/26/2023 | 123 | 34 | |
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 10 | 0 | 0 | 0 | 0 | ||||||||
| 27 | 14 | 0 | 0 | 0 | 0 | |||||||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | 1 | Y | 1 Rituximab | 600 | 45 | 45 | 42 | 26 | 10 | 2 | 10/23/2024 | 241 | 74 | |
| 2 Mosunetuzumab | 44 | 44 | 41 | 25 | 8 | 0 | ||||||||
| 89 | 89 | 83 | 51 | 18 | 2 | |||||||||
| Yes | A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | 1 | E | Total Registrations | 16 | 12 | 5 | 2 | 1 | 0 | 10/14/2023 | 177 | 75 | |
| 16 | 12 | 5 | 2 | 1 | 0 | |||||||||
| A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | 1 | E | Total Registrations | 17 | 12 | 5 | 1 | 0 | 0 | 01/03/2024 | 200 | 69 | ||
| 17 | 12 | 5 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 9 | 8 | 6 | 4 | 0 | 0 | 01/03/2024 | |||||
| 9 | 8 | 6 | 4 | 0 | 0 | |||||||||
| AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | 1 | E | Total Registrations | 51 | 34 | 21 | 14 | 2 | 0 | 08/15/2023 | 272 | 128 | ||
| 51 | 34 | 21 | 14 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 42 | 29 | 19 | 13 | 6 | 2 | 08/15/2023 | |||||
| 42 | 29 | 19 | 13 | 6 | 2 | |||||||||
| No | ANHL1931-PMBCL, Chemo-Immunotherapy +/- Nivo | 1 | E | Total Registrations | 33 | 11 | 6 | 2 | 0 | 0 | 02/28/2022 | 231 | 107 | |
| 33 | 11 | 6 | 2 | 0 | 0 | |||||||||